Holen Sie sich die Stockscreener-App
54.91
4.71%
2.47
Handel nachbörslich:
55.59
0.68
+1.24%
Tempus Ai Inc Aktie (TEM) Neueste Nachrichten
Artificial Intelligence Stocks To Follow NowFebruary 6th - MarketBeat
IQ EQ FUND MANAGEMENT IRELAND Ltd Boosts Stock Position in Tempus AI, Inc. $TEM - MarketBeat
Do Tempus AI’s New IPS Results Reframe TEM’s Edge In Precision Oncology Diagnostics? - Yahoo Finance
Best Artificial Intelligence Stocks To ResearchFebruary 5th - MarketBeat
Can Tempus AI’s (TEM) Immune Profile Score Redefine Its Edge In Precision Oncology Data? - simplywall.st
Tempus AI Links Hereditary Cancer Data And Immune Scoring To Growth Prospects - Yahoo Finance
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Globe and Mail
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought - The Motley Fool
Tempus AI, Inc. (TEM): A Bull Case Theory - Finviz
Insider Sell: David Epstein Sells 370 Shares of Tempus AI Inc (T - GuruFocus
Tempus AI (NASDAQ:TEM) Director Sells $21,981.70 in Stock - MarketBeat
Promising Artificial Intelligence Stocks To Watch NowFebruary 4th - MarketBeat
RSI Alert: Tempus AI (TEM) Now Oversold - Nasdaq
Tempus AI Stock (TEM) Opinions on Q4 Earnings Beat - Quiver Quantitative
New DNA study could sharpen cancer risk for thousands of patients - stocktitan.net
Tempus AI, Inc. (NASDAQ:TEM) Given Average Recommendation of "Hold" by Brokerages - MarketBeat
AI in Oncology Market to Reach US$ 22.85 Billion by 2033, Growing - openPR.com
Best Artificial Intelligence Stocks To Watch TodayFebruary 2nd - MarketBeat
Tempus AI, Inc. (TEM) Investor Outlook: Navigating a 46.97% Upside Amidst High Growth and Strategic Collaborations - DirectorsTalk Interviews
What's Going On With Tempus AI Stock Monday?Tempus AI (NASDAQ:TEM) - Benzinga
RNA in cancer gene tests found 1 in 25 positives otherwise missed - stocktitan.net
Artificial Intelligence Stocks To Keep An Eye OnFebruary 1st - MarketBeat
Tempus AI, Inc. (TEM) Strengthens Precision Medicine with New Tools, Partnerships, and Growth Milestones - Finviz
Mirae Asset Global Investments Co. Ltd. Increases Stake in Tempus AI, Inc. $TEM - MarketBeat
Artificial Intelligence Stocks To Follow TodayJanuary 31st - MarketBeat
Insider Selling: Tempus AI (NASDAQ:TEM) CEO Sells 166,250 Shares of Stock - MarketBeat
Promising Artificial Intelligence Stocks To Watch TodayJanuary 30th - MarketBeat
Tempus AI Enhances AI-Driven Diagnostics With Multiple FDA Approvals - MSN
Tempus AI Inc (TEM) Trading Down 4.09% on Jan 30 - GuruFocus
Esoteric Testing Research Report 2026 - GlobeNewswire Inc.
Is Tempus AI Inc. stock a good dividend stockWeekly Trade Review & Community Verified Swing Trade Signals - mfd.ru
Tempus AI's COO Ryan Fukushima sells shares worth $2.27 million - MSN
Artificial Intelligence Stocks Worth WatchingJanuary 29th - MarketBeat
Top Artificial Intelligence Stocks To Watch TodayJanuary 3rd - MarketBeat
TEM vs. DOCS: Which Medical-Tech Stock Looks Promising Amid AI Boom? - Finviz
21,000 Shares in Tempus AI, Inc. $TEM Purchased by Hussman Strategic Advisors Inc. - MarketBeat
Should Tempus AI’s (TEM) New Immunotherapy Prediction Data Shift How Investors View Its Moat? - simplywall.st
Tempus AI (TEM) Valuation Check After New Immune Profile Score Data And High Profile Investor Interest - Yahoo Finance
Tempus AI study shows improved cancer immunotherapy prediction By Investing.com - Investing.com Australia
Tempus AI Expands Cancer Tools As Shares Trade Below Analyst Estimates - Yahoo Finance
Tempus AI’s Clinical Breakthrough: A Potential Catalyst for Growth - AD HOC NEWS
Tempus AI IPS Study Points To Wider Immunotherapy Use And Investor Interest - simplywall.st
Is It Time To Reassess Tempus AI (TEM) After Its Strong 1 Year Share Price Run? - Yahoo Finance UK
Tempus says AI-powered biomarker improves immunotherapy predictions - FirstWord Pharma
Artificial Intelligence Stocks To Watch NowJanuary 27th - MarketBeat
Promising Artificial Intelligence Stocks To Follow TodayJanuary 4th - MarketBeat
Nancy Pelosi Just Doubled Down on AI Again - Yahoo Finance
Tempus Says Study Shows AI-Driven Test More Accurately Predicts Immunotherapy Benefits - marketscreener.com
Tempus Ai, Inc. Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers - marketscreener.com
Tempus AI study shows improved cancer immunotherapy prediction - Investing.com
Tempus Reveals Its AI-Driven IPS Test More Accurately Predicts Immunotherapy Benefit Compared to Conventional Biomarkers - Business Wire
Why Cathie Wood Is Trading Genomics Stocks for Tempus AI and WeRide - Blockonomi
Tempus AI, Inc. $TEM Shares Purchased by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Cathie Wood Dumps Biotech Stocks, Loads Up on AI and Self-Driving Companies - CoinCentral
Cathie Wood bets big on these AI stocks - MSN
Cathie Wood Sells Biotech Stocks, Bets Big on Tempus AI and WeRide - TipRanks
Cathie Wood Bets Big On AI Trifecta: Ark Deploys $1.4 Million Across Medical, Autonomous Driving Sectors - Benzinga
Cathie Wood’s ARK sells Twist Bioscience stock, buys Tempus AI and WeRide - Investing.com Nigeria
Cathie Wood’s ARK sells Twist Bioscience stock, buys Tempus AI and WeRide By Investing.com - Investing.com South Africa
3.44%
16.78%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):